Philogen Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dario Neri

Algemeen directeur

€150.0k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	27.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Dario Neri (60 yo)

27.5yrs

Tenure

€150,000

Compensatie

Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...

Philogen Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Insufficient new directors

Recent updates

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Q3, 2024 Results on Nov 07, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Insufficient new directors

CEO

Tenure

Compensatie